Nycomed has granted Sepracor, Inc. (NASDAQ: SEPR) the exclusive development, marketing and commercialisation rights for Ciclesonide in the United States. Ciclesonide is Nycomed’s patented corticosteroid with a novel principle of action. It is the active ingredient in the ALVESCO® Inhalation Aerosol for the treatment of asthma and in the Omnaris™ Nasal Spray for the treatment of allergic rhinitis. The agreement complements Sepracor’s respiratory portfolio and is a boost to Nycomed’s partnering approach for the United States.
For further Information:Media: Tobias CottmannDirector External CommunicationsPhone: +41 (0)44 55515-10
Investors:Christian B. SeidelinVice President ControllingTreasury and InsurancePhone:+41 (0) 44 55511-04